[1]
Peng J, Liang G, Inan S, et al. Dantrolene ameliorates cognitive decline and neuropathology in Alzheimer triple transgenic mice. Neurosci Lett 2012; 516(2): 274-9.
[http://dx.doi.org/10.1016/j.neulet.2012.04.008] [PMID: 22516463]
[http://dx.doi.org/10.1016/j.neulet.2012.04.008] [PMID: 22516463]
[2]
Chakroborty S, Briggs C, Miller MB, et al. Stabilizing ER Ca(2+) Channel function as an early preventative strategy for Alzheimer's disease. PLoS One 2012; 7(12): e52056.
[3]
Oules B, Del Prete D, Greco B, et al. Ryanodine receptor blockade reduces amyloid-beta load and memory impairments in Tg2576 mouse model of Alzheimer disease. J Neurosci 2012; 32(34): 11820-34.
[http://dx.doi.org/10.1523/JNEUROSCI.0875-12.2012] [PMID: 22915123]
[http://dx.doi.org/10.1523/JNEUROSCI.0875-12.2012] [PMID: 22915123]
[4]
Chami M, Checler F. Targeting Post-translational remodeling of ryanodine receptor: A new track for Alzheimer’s disease therapy? Curr Alzheimer Res 2020; 17(4): 313-23.
[http://dx.doi.org/10.2174/1567205017666200225102941] [PMID: 32096743.]
[http://dx.doi.org/10.2174/1567205017666200225102941] [PMID: 32096743.]
[5]
Abou MB, Sun L, Wei H. Approaches to optimizing dantrolene neuroprotection for treatment of Alzheimer’s disease. Curr Alzheimer Res 2020; 17(4): 324-8.
[6]
Wang J, Shi Y, Yu S, et al. Intranasal administration of dantrolene increased brain concentration and duration. PLoS One 2020; 15(3):e0229156.
[http://dx.doi.org/10.1371/journal.pone.0229156.] [PMID: 32160210]
[http://dx.doi.org/10.1371/journal.pone.0229156.] [PMID: 32160210]
[7]
Shi Y ZL, Gao X, Zhang J, et al. Intranasal dantrolene as a disease modifying drug in Alzheimer 5XFAD mice. Alzheimer Dementia 2019; 19(7): P597.
[8]
Inan S, Wei H. The cytoprotective effects of dantrolene: A ryanodine receptor antagonist. Anesth Analg 2010; 111(6): 1400-10.
[http://dx.doi.org/10.1213/ANE.0b013e3181f7181c.] [PMID: 20861418.]
[http://dx.doi.org/10.1213/ANE.0b013e3181f7181c.] [PMID: 20861418.]
[9]
Wu AJ, Tong BC, Huang AS, Li M, Cheung KH. Mitochondrial calcium signaling as a therapeutic target for Alzheimer’s disease. Curr Alzheimer Res 2020,; 17(4): 329-43.
[http://dx.doi.org/10.2174/1567205016666191210091302.] [PMID: 31820698.]
[http://dx.doi.org/10.2174/1567205016666191210091302.] [PMID: 31820698.]
Related Books
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research-Dementia
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Article Metrics
29
4